INVA
Innoviva IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.74B
P/E Ratio
7.05
EPS
$3.30
Beta
0.40
52W High
$25.14
52W Low
$16.52
50-Day MA
$22.17
200-Day MA
$20.23
Dividend Yield
—
Profit Margin
65.90%
Forward P/E
11.89
PEG Ratio
0.34
About Innoviva Inc
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Fundamentals
| Revenue (TTM) | $411.33M |
| Gross Profit (TTM) | $308.23M |
| EBITDA | $194.99M |
| Operating Margin | 34.70% |
| Return on Equity | 29.10% |
| Return on Assets | 7.18% |
| Revenue/Share (TTM) | $6.10 |
| Book Value | $15.71 |
| Price-to-Book | 1.45 |
| Price-to-Sales (TTM) | 4.22 |
| EV/Revenue | 3.421 |
| EV/EBITDA | 3.80 |
| Quarterly Earnings Growth (YoY) | 590.00% |
| Quarterly Revenue Growth (YoY) | 24.80% |
| Shares Outstanding | $74.05M |
| Float | $69.26M |
| % Insiders | 0.67% |
| % Institutions | 107.87% |
Analyst Ratings
Consensus ($33.20 target)
4
Buy1
SellData last updated: 4/8/2026